TriSalus Life Sciences (TLSI) Cash from Financing Activities (2022 - 2026)

TriSalus Life Sciences' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $42.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 337.5% year-over-year to $42.4 million in Q1 2026; TTM through Mar 2026 was $63.5 million, a 42.62% increase from a year earlier, with the FY2025 full-year figure at $30.8 million, down 18.91% from the prior year.
• Cash from Financing Activities climbed to $42.4 million in Q1 2026 per TLSI's latest filing, from $277000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $42.4 million in Q1 2026 and bottomed at $43000.0 in Q4 2023.
• The 5-year median for Cash from Financing Activities is $5.9 million (2022), against an average of $10.5 million.
• Across the five-year window, Cash from Financing Activities slumped 99.27% in 2023 and jumped 6862.79% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $5.9 million in 2022, then slumped by 99.27% to $43000.0 in 2023, then soared by 6862.79% to $3.0 million in 2024, then plunged by 90.75% to $277000.0 in 2025, then soared by 15201.44% to $42.4 million in 2026.
• Per Business Quant, the three latest TLSI Cash from Financing Activities figures stand at $42.4 million (Q1 2026), $277000.0 (Q4 2025), and $82000.0 (Q3 2025).